Nurix Therapeutics officer plans $137K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Christine Ring reported an intended sale of 8,148 common shares, with an aggregate market value of $136,967.88 and an approximate sale date of May 4, 2026. Morgan Stanley Smith Barney LLC is identified as the broker. Ring's remarks state that the shares came from restricted stock units that vested from May 2, 2022, through April 30, 2025. The listed plan adoption or instruction date, if relying on Rule 10b5-1, is November 10, 2025. Recent-sales information includes 5,394 shares sold on May 1, 2026, for gross proceeds of $90,406.68.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.